Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
72
XERS Quote, Financials, Valuation and Earnings
Last price:
$7.22
Seasonality move
:
-6.43%
Day range:
$7.17 - $7.32
52-week range:
$3.14 - $10.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.33x
P/B ratio:
--
Volume:
781K
Avg. volume:
2.1M
1-year change:
107.78%
Market cap:
$1.2B
Revenue:
$203.1M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$74.2M | $0.01 | 35.42% | -70% | $11.14 |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$773.8M | $0.14 | 10.63% | 774.45% | $14.00 |
|
ASRT
Assertio Holdings, Inc.
|
$27M | -- | -7.48% | -100% | $2.66 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.5M | -$0.04 | -1.06% | -93.96% | $7.16 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$7.21 | $11.14 | $1.2B | -- | $0.00 | 0% | 4.33x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$12.87 | $14.00 | $4B | 912.77x | $0.00 | 0% | 1.40x |
|
ASRT
Assertio Holdings, Inc.
|
$0.66 | $2.66 | $4.2M | -- | $0.00 | 0% | 0.47x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.57 | $7.16 | $78.6M | -- | $0.00 | 0% | 9.16x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
100.34% | -1.301 | 19.12% | 1.25x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
104.25% | 0.703 | 83.58% | 1.31x |
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.300 | 795.64% | 1.43x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -0.931 | 0.02% | 1.22x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings, Inc.
|
$60.7M | $6.7M | -6.45% | -1019.2% | 9.05% | $18.4M |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$274M | $72.8M | 2.24% | -587.3% | 9.28% | $96M |
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Xeris Biopharma Holdings, Inc. vs. Competitors
-
Which has Higher Returns XERS or AMRX?
Amneal Pharmaceuticals, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 2.31%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Amneal Pharmaceuticals, Inc.'s return on equity of -587.3%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B -
What do Analysts Say About XERS or AMRX?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 54.55%. On the other hand Amneal Pharmaceuticals, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 8.78%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 AMRXAmneal Pharmaceuticals, Inc.2 0 0 -
Is XERS or AMRX More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.667, which suggesting that the stock is 33.307% less volatile than S&P 500. In comparison Amneal Pharmaceuticals, Inc. has a beta of 1.365, suggesting its more volatile than the S&P 500 by 36.493%.
-
Which is a Better Dividend Stock XERS or AMRX?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Amneal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or AMRX?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are smaller than Amneal Pharmaceuticals, Inc. quarterly revenues of $784.5M. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than Amneal Pharmaceuticals, Inc.'s net income of $18.1M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Amneal Pharmaceuticals, Inc.'s PE ratio is 912.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 4.33x versus 1.40x for Amneal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.4.33x -- $74.4M $621K AMRXAmneal Pharmaceuticals, Inc.1.40x 912.77x $784.5M $18.1M
-
Which has Higher Returns XERS or ASRT?
Assertio Holdings, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of 23.14%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Assertio Holdings, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M ASRTAssertio Holdings, Inc.61.01% $0.11 $150.8M -
What do Analysts Say About XERS or ASRT?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 54.55%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $2.66 which suggests that it could grow by 303.47%. Given that Assertio Holdings, Inc. has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Xeris Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 ASRTAssertio Holdings, Inc.2 0 0 -
Is XERS or ASRT More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.667, which suggesting that the stock is 33.307% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.5%.
-
Which is a Better Dividend Stock XERS or ASRT?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or ASRT?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than Assertio Holdings, Inc. quarterly revenues of $49.5M. Xeris Biopharma Holdings, Inc.'s net income of $621K is lower than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 4.33x versus 0.47x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.4.33x -- $74.4M $621K ASRTAssertio Holdings, Inc.0.47x -- $49.5M $11.4M
-
Which has Higher Returns XERS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of -255.85%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About XERS or NBY?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 54.55%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Xeris Biopharma Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Xeris Biopharma Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is XERS or NBY More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.667, which suggesting that the stock is 33.307% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock XERS or NBY?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or NBY?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Xeris Biopharma Holdings, Inc.'s net income of $621K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 4.33x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.4.33x -- $74.4M $621K NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns XERS or PSTV?
Plus Therapeutics, Inc. has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of -316.61%. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About XERS or PSTV?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 54.55%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1151.53%. Given that Plus Therapeutics, Inc. has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Xeris Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 PSTVPlus Therapeutics, Inc.3 0 0 -
Is XERS or PSTV More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.667, which suggesting that the stock is 33.307% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.692%.
-
Which is a Better Dividend Stock XERS or PSTV?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or PSTV?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Xeris Biopharma Holdings, Inc.'s net income of $621K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 4.33x versus 9.16x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.4.33x -- $74.4M $621K PSTVPlus Therapeutics, Inc.9.16x -- $1.4M -$4.4M
-
Which has Higher Returns XERS or PTN?
Palatin Technologies has a net margin of 0.84% compared to Xeris Biopharma Holdings, Inc.'s net margin of --. Xeris Biopharma Holdings, Inc.'s return on equity of -1019.2% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings, Inc.81.57% $0.00 $256.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About XERS or PTN?
Xeris Biopharma Holdings, Inc. has a consensus price target of $11.14, signalling upside risk potential of 54.55%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Xeris Biopharma Holdings, Inc., analysts believe Palatin Technologies is more attractive than Xeris Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings, Inc.5 1 0 PTNPalatin Technologies0 0 0 -
Is XERS or PTN More Risky?
Xeris Biopharma Holdings, Inc. has a beta of 0.667, which suggesting that the stock is 33.307% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock XERS or PTN?
Xeris Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or PTN?
Xeris Biopharma Holdings, Inc. quarterly revenues are $74.4M, which are larger than Palatin Technologies quarterly revenues of --. Xeris Biopharma Holdings, Inc.'s net income of $621K is higher than Palatin Technologies's net income of --. Notably, Xeris Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings, Inc. is 4.33x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings, Inc.4.33x -- $74.4M $621K PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
